Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon receptor (GCP) for obesity, observers are already making comparisons of the drug ...

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc ...

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

Wegovy, a weight loss drug made famous by celebrities around the world, is on New Zealand pharmacists' shelves, but it is ...

Find insight on Innovent Biologics, Fisher & Paykel Healthcare and more in the latest Market Talks covering Health Care.

The weight loss and diabetes drug Wegovy (also known as Ozempic) which is only available on prescription, should be on pharmacy shelves as of 1 July, drug maker Novo Nordisk confirmed. It ends a years ...

Gyre Therapeutics has a unique business model for evaluating and commercializing drugs in China. Find out why GYRE stock is a ...